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Mutations, polymorphisms, RNA processing and post-translational modifications (PTMs) such as acetylation, methylation and phosphorylation can lead to a single gene 
producing many functionally distinct ‘proteoforms’1. These proteo-
forms can have different effects on important biological processes, 
including gene regulation, cell signaling and protein activity; con-
sequently, the ability to characterize these species is essential for an 
understanding of the biological response to disease. The identity of 
a proteoform can often be inferred2 from an accurate experimentally 
determined intact mass3. One can increase the sensitivity of intact-
mass-based proteoform identification by determining the relative 
abundance of a particular amino acid by using isotopic labeling, 
by using mass similarities to cluster proteoforms into gene families 
and by reducing the search space using sample-specific search data-
bases2. Localizing PTMs, and in some cases the definitive proteo-
form identifier, requires tandem mass spectrometry (MSn) analysis. 
The measurement of intact protein mass followed by MSn has been 
coined ‘top-down’ mass spectrometry4–8, with its origins in Fenn 
and colleagues’ discovery that large biomolecules could be ionized9 
and fragmented10–12 using electrospray ionization (ESI)-MS. Top-
down MS protocols, unlike widely used bottom-up protocols13,14, do 
not require endoproteinase digestion before analysis, do not con-
flate proteoforms and tend to complement native MS analysis.
One advantage of ESI over the alternative ‘soft’ ionization 
method, matrix-assisted laser desorption-ionization (MALDI), is 
that ESI imparts more charge per protein. This enables the mass 
determination of large biomolecules using mass analyzers with 
moderate mass-to-charge ratio upper limits (for example, m/z ≤ 
4,000), which happen to offer the highest resolving power. Higher 
charge per molecular mass also facilitates gas-phase fragmentation 
and, therefore, the characterization of primary sequence and PTMs 
by MSn (refs. 15,16). Because of this superior fragmentation and the 
ability to interface with liquid chromatography (LC) systems, ESI is 
used for most top-down MS experiments. Projects requiring rapid 
MS analysis17, the ability to analyze hundreds of proteins in a single 
spectrum, protein imaging capabilities, or less signal suppression 
by common protein buffer components18 may be better suited for 
MALDI-MS.
Compared to bottom-up workflows, top-down approaches pro-
vide additional layers of information, including detecting modi-
fications that are removed or scrambled19 during peptide sample 
preparation (for example, S-thiolation), elucidating functional 
relationships (for example, cross-talk) between PTMs on the same 
protein molecule, characterizing drug–target interactions, observ-
ing important modifications on biopharmaceuticals, and identi-
fying and quantifying distinct proteoforms that would have been 
convoluted by endoproteinase digestion20–24. In addition, sample 
preparation for intact protein MS comprises fewer steps than bot-
tom-up approaches and does not require chemical modification (for 
example, reduction and alkylation), thereby reducing the number of 
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experimental artifacts25. Current top-down sample cleanup meth-
ods (for example, protein precipitation26 and molecular weight cut-
off (MWCO) ultrafiltration) are not applicable to all sample types or 
downstream MS analyses. The demand for robust, generally appli-
cable methods for intact protein MS is the most common request 
made to members of the Consortium for Top-Down Proteomics27,28 
(http://topdownproteomics.org/).
Our goal here is to address this unmet need, by providing a 
guide to enable users with all levels of expertise to acquire high-
quality intact protein mass spectra by ESI-MS. First we discuss 
signal suppression associated with common buffer components 
and biotherapeutic excipients. This provides the rationale for most 
failed intact MS measurements and, in addition, a path to designing 
MS-compatible buffers. Then, we present a decision tree based on 
sample composition and experimental goals, which guides users to 
a best-practices protocol and corresponding benchmark data.
Origins of signal suppression and signal spreading
Biological, biochemical and biotherapeutic sample preparations 
usually contain numerous interfering substances (for example, 
salts, detergents, chaotropes and buffers) that lead to signal sup-
pression during ESI-MS analysis. To provide a theoretical context, 
we describe the two major drivers of the quality of intact protein 
(positive ion) ESI-MS and how these are affected by interfering sub-
stances. The first driver of quality is the formation of desolvated 
protein ions, which can be understood in terms of a few critical steps 
during the ESI process16,29,30. Interfering substances generally affect 
the ESI process after the formation of nanodroplets at the Rayleigh 
charge limit. Two salient, often opposing, processes that occur 
within these nanodroplets are the partitioning of net charge toward 
the droplet surface and the minimization of solvation energy. Polar 
species such as salts and native proteins partition toward the drop-
let interior to optimize solvation energy; their ionization, therefore, 
requires evaporation of solvent molecules16. Hydrophobic species 
such as detergent monomers and unfolded proteins migrate to the 
droplet surface to optimize solvation energy and, in a faster pro-
cess that requires less energy, evaporate or are ejected. Many of the 
techniques presented here for reducing signal suppression can be 
rationalized within the framework above. For example, organic sol-
vents that decrease surface tension should promote the ionization 
of both polar and nonpolar analytes; detergents partition to the sur-
face, where they can outcompete analytes for a limited number of 
protons; organic solvents and acids that unfold proteins should pro-
mote ejection-based ionization; native MS (nMS) requires greater 
desolvation energy and is more sensitive to polar contaminants.
The second driver of the quality of intact protein MS is signal 
spreading (that is, the distribution of the signal from a single pro-
teoform across multiple channels), which increases with protein 
mass. Each channel has its own respective noise; consequently, the 
cumulative noise increases proportionally to the number of chan-
nels. The ESI process promotes signal spreading, via adduct forma-
tion, by increasing the concentrations of interfering substances and 
proteins. Heavy isotopes and charge states further distribute signal 
intensity across multiple channels; the former can be mitigated by 
isotope depletion31. Here we describe experimental techniques that 
minimize signal spreading (increase signal-to-noise ratio, or S/N), 
including using nMS to reduce the number of charge states, and the 
use of volatile salts (for example, ammonium acetate) or purifica-
tion to minimize the effects of alkaline salts.
Signal suppression by common buffer components
Using the intact protein standard mixture (ubiquitin, myoglobin, 
trypsinogen and carbonic anhydrase) established by the National 
Resource for Translational and Developmental Proteomics 
(NRTDP) (http://nrtdp.northwestern.edu/protocols/), we evaluated 
common buffer components (Fig. 1) to quantify the concentration 
required for 50% signal suppression during direct infusion ESI. By 
analogy to half-maximum inhibitory concentration (IC50) nomen-
clature, we termed this metric the half-maximum suppression con-
centration (SC50) (Fig. 1, Supplementary Fig. 1). At their typical 
concentrations, all common buffer additives suppressed ESI signal 
considerably. Consistent with the mechanisms of ESI ionization 
described above, detergents produced the most signal suppression, 
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Fig. 1 | Common buffer components suppress MS signal. a, MgCl2 
reduces signal (and S/N) in a concentration-dependent manner. b, Fit 
of experimental data to determine the concentration of MgCl2 required 
for 50% signal suppression (SC50; black arrow), c, Table of common 
buffer components and the concentration threshold for 50% SC50 
(experimental data curves and their fits are shown in Supplementary Fig. 
1) and calculations in Supplementary Note 2. Detergents compatible with 
mass spectrometry are discussed in Protocol 2b. *Signal suppression by 
detergents is less pronounced above their critical micellar concentration 
(CMC) (described in Protocol 2b).
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less volatile (for example, metallic) salts produced intermediate sup-
pression and volatile components lowest suppression. Additional 
details of the experimental parameters used here are provided in 
Supplementary Notes 1 and 2.
The SC50 values given in Fig. 1 allow users to design 
MS-compatible buffers. In addition, the SC50 and buffer composi-
tion serve as the entry point into the decision tree outlined below, 
leading users to the appropriate protocol. Although the trends in 
SC50 values reported here should generally be consistent across MS 
platforms, parameter-dependent variations in the reported values 
are likely (in particular, flow rate, voltages, temperatures, and pres-
sures that affect ionization and desolvation). Here, for example, we 
calculated SC50 obtained by direct infusion using a standard micro-
flow ESI source (about a microliter per minute), but nano-ESI (less 
than a microliter per minute) is less affected by salts because of the 
order-of-magnitude decrease in initial droplet size32,33.
Intact protein MS (IPMS) decision tree
The IPMS decision tree (Fig. 2) directs practitioners to a protocol 
or a combination of protocols based on buffer composition, the 
number of proteins in the sample, and whether native or denaturing 
conditions are to be used. Consider, for example, a purified pro-
tein in phosphate-buffered saline (PBS). Based on the 1.5 mM SC50 
exhibited by NaCl (Fig. 1c) and the 137 mM NaCl present in PBS, 
a protein sample in PBS requires a 91-fold dilution to achieve 50% 
of the potential MS signal. Therefore, if the protein concentration is 
greater than 90 µM and salt adducts will not impede data analysis, 
the sample can be diluted following Protocol 1. Otherwise, sample 
cleanup by ultrafiltration using spin cartridges with a MWCO-
membrane is recommended following Protocol 2.
Interest in certain PTMs (for example, metallation) or pro-
tein complex quaternary structure would dictate the use of native 
MS methods following Protocol 4b; otherwise the denaturing MS 
Protocol 4a is recommended. Depending on the complexity of the 
sample, additional separation techniques such as GELFrEE may 
be required (Supplementary Fig. 2). The objective of this decision 
tree is to provide a proven workflow for any sample, not to rule out 
alternative methods. For example, depending on sample stability, 
user expertise and available resources, precipitation (Protocol 3), 
size exclusion ‘spin cartridges’, or LC (Protocol 5) could be suitable 
alternatives to MWCO ultrafiltration. All protocols and bench-
marks referenced by the decision tree and alternative methods are 
summarized below and further detailed in Supplementary Notes 
1−5 and Supplementary Protocols 1−5.
Protein standards and benchmarks
To promote standardization and allow users to benchmark their 
own data using readily available proteins, we provided represen-
tative results for each protocol using the following commercially 
available standards: (i) the NRTDP intact protein standard mix-
ture (see Supplementary Note 1 for preparation instructions), 
(ii) NIST monoclonal antibody reference material 8671 (NISTmAb), 
containing humanized IgG1ĸ in 12.5 mM L-histidine, 12.5 mM 
L-histidine HCl (pH 6.0), and (iii) Sigma bacteriorhodopsin from 
Halobacterium salinarum (B0184). Benchmarks for mass accu-
racy depend upon the instrumentation platform and have been 
reviewed3,34–39. Rules of thumb include requiring 10 p.p.m. accuracy 
for modern Fourier transform MS and 20 p.p.m. accuracy for mod-
ern quadrupole time-of-flight (QTOF) MS. We suggest the use of 
ProForma notation40 for standardized proteoform nomenclature, 
and note that the PeptideMass tool (https://web.expasy.org/pep-
tide_mass/) can be used to calculate the mass of a given sequence or 
of proteoforms contained in the UniProt database.
Protocol 1: sample preparation by dilution of interfering 
substances
Consistent with the mechanisms of ESI and signal spreading detailed 
above, common buffer components render proteins undetectable by 
MS (Fig. 3). Minimally complex, concentrated protein solutions can 
often be analyzed by direct infusion, following dilution to ~1 µM 
final protein concentration in the appropriate sample buffer. Users 
should consider using this protocol if dilution can decrease the con-
centration of a given interfering substance below its SC50 value (Fig. 1, 
Supplementary Protocol 1). Assuming a practical upper limit of 
~10 mM protein concentration, this protocol is potentially appli-
cable to any of the components listed in Fig. 1. As detailed above, 
however, nMS utilizes an ESI process that is more sensitive to many 
interferents, including salts. Consequently, dilution is less likely to 
adequately improve nMS. Protocol 4 describes methods to dilute 
native proteins into whichever solution will be used to introduce 
samples to the MS. However, mass spectra obtained by this method 
have the lowest S/N of any of the protocols described here and may 
contain adducts.
Protocol 2: sample preparation using MWCO ultrafiltration
We recommend remediating nonvolatile salt adducts by buffer 
exchange into a solution of volatile salts. The MWCO of the ultra-
filtration device should not exceed half the molecular mass of any 
given protein in a sample to prevent possible sample loss. No par-
ticular pH is optimal for all proteins, but pH extremes should be 
avoided, as should pH that is equivalent to a protein’s pI, where 
protein solubility is at a local minimum41. We recommend using 
ammonium acetate throughout these protocols owing to its volatil-
ity and ability to act as a stabilizing background electrolyte during 
ESI42. Ammonium acetate provides maximal buffering around pH 
4.75 (acetate) and 9.25 (ammonium), and results in a neutral pH 
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Fig. 2 | Decision tree for intact protein sample clean-up, preparation and 
analysis. The red dashed line, for example, denotes the decision path for 
the native MS analysis of a membrane protein. *LC can also be applied 
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prepared following Protocol 3 can be analyzed via denaturing direct 
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upon dissolving in water (approximate pH 6.5−7). Before adding 
protein sample, MWCO-ultrafiltration devices should be rinsed 
with the appropriate buffer. Additional details for this method can 
be found in Supplementary Protocol 2.
Protocol 2a, soluble proteins. On the basis of the protein masses 
in the NRTDP intact protein standard, we recommend using a 
MWCO of 3 kDa according to the manufacturer’s instructions. The 
protein preparation should be subjected to three (1:20 dilution) 
buffer exchanges into 10 mM ammonium acetate (pH 6.5) using 
a MWCO-ultrafiltration device, followed by an additional three 
exchanges into 2.5 mM ammonium acetate (pH 6.5) (exemplary 
data in Fig. 3, Supplementary Figs. 3 and 4, see also Supplementary 
Protocol 2a and Supplementary Note 3). Denaturing and nonde-
naturing samples can then be diluted and introduced to the MS as 
described below in Protocol 4a.
Protocol 2b, native membrane proteins. Membrane proteins are 
estimated to account for 23% of the total human proteome and rep-
resent ~60% of targets for currently approved drugs43,44. The mass 
analysis of native, intact membrane proteins can further provide key 
information regarding stoichiometry, ligand binding and lipid asso-
ciation. A typical analysis of a membrane protein complex requires 
either size-exclusion chromatography (SEC) or MWCO ultrafiltra-
tion to remove alkali salt adducts while maintaining the detergent 
used to solubilize the protein (Supplementary Protocol 2b)45. This 
differs fundamentally from the MWCO ultrafiltration used during 
filter-aided sample preparation (FASP) to improve the bottom-up 
proteomics analysis of membrane proteins, which removes deter-
gents46,47. For users interested in native membrane proteins, we 
recommend the protocols of Robinson and coworkers45. Their 
protocols are based on comprehensive optimization and include 
a complete list of non-ionic detergents compatible with MS and 
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detailed sample preparation considerations. We demonstrate an 
example application of Robinson and coworkers’ protocols for 
the native tetramer of Aquaporin Z (AqpZ) from Escherichia coli 
(Supplementary Fig. 5).
Protocol 3: sample preparation using protein precipitation
Common precipitation protocols use organic solvents to agglomer-
ate proteins while leaving small molecules, including salts and deter-
gents, solubilized. Whereas MWCO ultrafiltration using Protocol 2a 
does not rescue protein signal from a preparation containing harsh 
surfactants (for example, SDS and Triton), precipitation of proteins 
following Protocol 3 does (Fig. 3, Supplementary Protocol 3). A vol-
ume ratio of 1:1:4:3 of aqueous protein sample:chloroform:methan
ol:water is recommended to precipitate proteins26. The supernatant 
is removed by aspiration, and the precipitated pellet can be further 
washed with one more addition and removal of methanol. Pellets 
are resolubilized for 15 minutes at −20 °C using a small volume of 
80% (v/v) formic acid (~25% of the starting volume) and are then 
diluted to the starting sample volume with HPLC-grade water or a 
solution of volatile salts (for example, ammonium acetate)48. As an 
alternative method, acetone precipitation has the distinct advantage 
of leaving many proteins folded. This method, however, has been 
shown to modify proteins with +98 Da adducts49, requires longer 
incubation at −20 °C (at least 1 h), requires that all steps be per-
formed at or below 0 °C to maximize resolubilization, and can be 
compromised by detergents.
Protocol 4a: denaturing direct-infusion MS
Denaturing direct-infusion ESI mass spectra can usually be obtained 
by introducing samples to the MS in a mixture of 49.95% HPLC-
grade acetonitrile, 49.95% HPLC-grade water, and 0.1% formic 
acid (v/v). A 60:35:5 ratio of HPLC-grade methanol:water:acetic 
acid may be used as an alternative and, in some cases, can improve 
S/N9,50. As described above, the use of these organic solvents and 
acids results in efficient ionization from a droplet’s surface, often 
allowing MS analysis to be performed using instrumentation 
parameters typically used for peptides. A more detailed description 
of instrument parameters for the Bruker SolariX FT-ICR MS used 
during denaturing direct infusion studies is found in Supplementary 
Protocol 4a.
Protocol 4b: native direct-infusion MS
Although native MS protocols may not necessarily produce folded 
ions that match exactly to their in-solution structures, they can be 
used to achieve accurate mass measurements of native structures 
and complexes51. Consequently, native direct-infusion MS can pro-
vide unique structural information, including the characterization 
of labile PTMs, metal-binding sites, noncovalent interactions with 
small molecules, and protein tertiary and quaternary structure. 
Detergent-free samples can be infused directly in aqueous 2.5 mM 
ammonium acetate52, the same solution used in the final stage of 
Protocol 2a (concentrations of ammonium acetate up to 500 mM 
can even be used).
Figure 4 compares mass spectra of carbonic anhydrase in dena-
tured and native states, with the intensity of the base peak in the 
native sample being about twofold higher than that of the denatured 
sample. This comparison was repeated in four additional labs on 
six different instruments to illustrate the possible range of relative 
intensities (Supplementary Fig. 6, Supplementary Protocol 4b). 
Membrane protein complexes with MS-compatible detergents can 
be infused directly from the final solution described in Protocol 2b45. 
To observe native membrane proteins, detergent ions must be 
removed from the protein–micelle complex by increased colli-
sional activation. This may be achieved through an increase in col-
lision voltage applied to the source or the collision cell (typically 
50−200 V), but it could require additional critical parameters that 
are described in detail by Robinson and coworkers, and in part in 
Supplementary Protocol 4b45,53,54.
Protocol 5: intact protein analysis using LC-MS
Ionization suppression by excipients and by other proteins generally 
makes the analysis of multiple proteins and proteoforms by direct 
infusion intractable. For example, many ‘high-purity’ proteins (as 
judged by SDS-PAGE) contain numerous proteoforms that cannot 
be reliably detected and quantitatively assessed without up-front 
separation55,56. Liquid phase separation approaches, including LC 
(for example, reversed-phase (RP), size-exclusion, ion exchange, 
chromatofocusing) and capillary electrophoresis techniques (for 
example, capillary zone electrophoresis, capillary isoelectric focus-
ing) can remove excipients and provide the resolving power for deep 
characterization of proteins. As directed in the decision tree (Fig. 2), 
separation of particularly complex samples (>100 proteins) requires 
an additional dimension of separation before LC-MS. Supplementary 
Fig. 2 shows the use of GELFrEE separation prior to LC, which frac-
tionates samples on the basis of protein molecular weights and has 
resulted in the largest number of characterized proteoforms to date57.
Protocol 5a: LC-MS of soluble proteins. RP-LC is recommended 
for all samples containing more than five unique proteins but is also 
a viable option for samples with fewer proteins, provided they do 
not contain high salt concentrations (>1 M) or harsh detergents. 
The recommended reversed-phase LC protocol is described in 
Supplementary Protocol 5a and at http://nrtdp.northwestern.edu/
protocols/.
Figure 5 demonstrates that sufficient intact MS signal was 
attained, and four unique chromatographic peaks were observed, 
using Protocol 5a with a PLRP-S stationary phase (1,000-Å pore 
size, 5-µm particle size) on a Dionex UPLC coupled to a Thermo 
Orbitrap Elite. We provide benchmarks for this standard operat-
ing procedure (SOP), as well as for additional data acquired using 
Monolithic and C4 stationary phases, for six widely used platforms 
(Waters Xevo G2-S QTOF, Supplementary Fig. 7; Bruker Impact II 
QTOF and Bruker SolariX FT-ICR, Supplementary Fig. 8; Thermo 
Orbitrap Elite, Thermo Orbitrap Fusion Lumos, and Thermo 
Orbitrap QE-HF, Supplementary Figs. 9 and 10). To allow users to 
compare their performance with that of experienced operators using 
instruments that are operating within specifications, we report S/N 
for the platforms used here (Fig. 5). However, instrument vendors 
use proprietary, non-standardized techniques to preprocess data, 
display data and determine S/N, and, as a result, our data cannot 
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be used for a cross-platform comparison. As an example of a viable 
alternative method that is notably better suited for proteoforms with 
similar mass and RP-LC retention (for example, deamidation), we 
provide a separation of the same protein mix using capillary zone 
electrophoresis (Supplementary Fig. 11).
Protocol 5b: intact membrane protein LC-MS. Denaturing 
LC-MS of intact membrane proteins is not straightforward because 
of their inherent hydrophobicity58,59. Whitelegge et  al. provided 
the earliest example of denaturing LC-MS of membrane proteins 
using high concentrations of mobile phase additives and demon-
strated that ESI of membrane proteins could achieve the 0.01% mass 
accuracy benchmark established for ESI of soluble proteins58. For 
thorough reviews of the current state of membrane protein analysis 
via LC-MS60,61 and the corresponding protocols, we direct readers 
to refs. 60–62.
Current denaturing LC-MS methods for membrane proteins use 
either size-exclusion63,64 or reversed-phase separation. Owing to the 
ease of implementation across a variety of MS platforms, we sug-
gest analysis via reversed-phase LC-MS using a polystyrene-divinyl 
benzene co-polymer stationary phase (PLRP-S, 300 Å, Agilent). We 
do not recommend the use of long chain bonded stationary phases 
such as C8 and C18, as membrane proteins are likely to be retained 
on the column. As an example, we solubilized enriched bacteri-
orhodopsin from H. salinarum (Sigma B0184) in 88% formic acid 
to separate the protein from lipid contaminants. To avoid the risk of 
formic acid adduction (+28 Da), samples are immediately injected 
onto the column and solvent exchanged to much lower acid con-
centrations (0.1%). In the case of membrane protein preparations 
containing high enough concentrations of lipid contaminants to 
confound analysis or damage the column, we recommend precipi-
tation following Protocol 3 before analysis. Proteins are eluted using 
an increasing gradient of 49.95% acetonitrile, 49.95% isopropanol, 
0.1% formic acid. Figure 6 shows the analysis of denatured bacte-
riorhodopsin of H. salinarum following this protocol. Although 
elution efficiency for some integral proteins may fall well below 
100%, PLRP-S columns can be regenerated with 90% formic acid 
injections. This protocol was performed in five labs on five differ-
ent instrument platforms (Supplementary Fig. 12, Supplementary 
Protocol 5b). An example of an alternative LC-MS method using 
a more common stationary phase (ZORBAX RRHD 300SB-C3) is 
provided for aquaporin Z in Supplementary Fig. 5b.
Special methodological considerations for intact antibody 
mass spectrometry
With the increasing development of biotherapeutics and biosimilars 
in the pharmaceutical industry, and an increasingly stringent route 
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to regulatory approvals, there is a growing need for intact antibody 
MS. Every protocol presented here can be applied to the analysis 
of intact antibodies (Fig. 3, Supplementary Fig. 13, Supplementary 
Note 4). However, as antibodies are relatively large and signal 
spreading increases in proportion to protein size, we recommend 
against the use of Protocol 1 (dilution) for any regulatory filing.
Discussion
The IPMS decision tree (Fig. 2) guides practitioners of all levels 
toward broadly applicable methods to obtain high-quality intact 
mass spectra from any protein sample. The protocols described here 
have been scrutinized and optimized in over ten expert intact pro-
tein MS labs, and successfully applied in laboratories without expe-
rience in intact protein MS. We hope that these protocols will enable 
any research group to adopt intact protein mass analysis.
The accurate mass measurement of an intact protein is the sine 
qua non of top-down mass spectrometry, which can characterize 
how proteoforms interact and identify PTMs that are lost in other 
analyses. High-throughput top-down analysis of whole proteomes 
has proven successful in the unambiguous identification of hun-
dreds of proteins and proteoforms from a single biological sample65 
and revealed prevalent yet previously uncharacterized biologically 
relevant modifications66. Quantitative top-down proteomics has 
been used to identify disease-relevant differences in protein levels, 
an encouraging step forward in the field of proteomics-based per-
sonalized medicine67. Additionally, by using native mass spectrom-
etry following the top-down workflow, one can observe previously 
unknown protein–protein interactions, protein–ligand binding, 
protein–cofactor association and protein-complex stoichiometry, 
and assess their relationships to important biological pathways68. 
We believe that by starting with intact mass analysis, using these 
intact protein MS protocols coupled to top-down MS analysis, and 
by identifying proteoforms rather than proteins, scientists can gain 
new insights into the human proteome. We also hope that these pro-
tocols serve as a starting point for users to push, even further, the 
current limits of high-molecular-weight mass spectrometry.
All general protocols are available as Supplementary Protocols.
Received: 29 December 2017; Accepted: 21 May 2019;  
Published online: 27 June 2019
References
 1. Smith, L. M. & Kelleher, N. L. Proteoform: a single term describing protein 
complexity. Nat. Methods 10, 186–187 (2013).
 2. Shortreed, M. R. et al. Elucidating proteoform families from proteoform 
intact-mass and lysine-count measurements. J. Proteome Res. 15,  
1213–1221 (2016).
 3. Mann, M. & Kelleher, N. L. Precision proteomics: The case for high 
resolution and high mass accuracy. Proc. Natl Acad. Sci. USA 105,  
18132 (2008).
 4. Shaw, J. B. et al. Complete protein characterization using top-down mass 
spectrometry and ultraviolet photodissociation. J. Am. Chem. Soc. 135, 
12646–12651 (2013).
 5. Ge, Y. et al. Top down characterization of larger proteins (45 kDa) by 
electron capture dissociation mass spectrometry. J. Am. Chem. Soc. 124, 
672–678 (2002).
 6. Siuti, N. & Kelleher, N. L. Decoding protein modifications using top-down 
mass spectrometry. Nat. Methods 4, 817–821 (2007).
 7. Ge, Y., Rybakova, I. N., Xu, Q. G. & Moss, R. L. Top-down high-resolution 
mass spectrometry of cardiac myosin binding protein C revealed that 
truncation alters protein phosphorylation state. Proc. Natl Acad. Sci. USA 
106, 12658–12663 (2009).
 8. Toby, T. K., Fornelli, L. & Kelleher, N. L. Progress in top-down proteomics 
and the analysis of proteoforms. Annu. Rev. Anal. Chem. 9, 499–519 (2016).
 9. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F. & Whitehouse, C. M. 
Electrospray ionization for mass spectrometry of large biomolecules. Science 
246, 64–71 (1989).
 10. Loo, J. A., Edmonds, C. G. & Smith, R. D. Tandem mass spectrometry of very 
large molecules: serum albumin sequence information from multiply charged 
ions formed by electrospray ionization. Anal. Chem. 63, 2488–2499 (1991).
 11. Reid, G. E. & McLuckey, S. A. ‘Top down’ protein characterization via 
tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 37, 663–675 (2002).
 12. Alexandrov, M. L. et al. Extraction of ions from solutions under atmospheric 
pressure as a method for mass spectrometric analysis of bioorganic 
compounds. Rapid Commun. Mass Spectrom. 22, 267–270 (2008).
 13. McCormack, A. L. et al. Direct analysis and identification of proteins in 
mixtures by LC/MS/MS and database searching at the low-femtomole level. 
Anal. Chem. 69, 767–776 (1997).
 14. Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C. & Yates, J. R. Protein analysis 
by shotgun/bottom-up proteomics. Chem. Rev. 113, 2343–2394 (2013).
 15. Kelleher, N. L. et al. Top down versus bottom up protein characterization  
by tandem high-resolution mass spectrometry. J. Am. Chem. Soc. 121, 
806–812 (1999).
 16. Konermann, L., Ahadi, E., Rodriguez, A. D. & Vahidi, S. Unraveling the 
mechanism of electrospray ionization. Anal. Chem. 85, 2–9 (2013).
 17. Lohnes, K. et al. Combining high-throughput MALDI-TOF mass 
spectrometry and isoelectric focusing gel electrophoresis for virtual 2D 
gel-based proteomics. Methods 104, 163–169 (2016).
 18. Fenselau, C. & Demirev, P. A. Characterization of intact microorganisms by 
MALDI mass spectrometry. Mass Spectrom. Rev. 20, 157–171 (2001).
 19. Auclair, J. R. et al. Artifacts to avoid while taking advantage of top-down 
mass spectrometry based detection of protein S-thiolation. Proteomics 14, 
1152–1157 (2014).
 20. Auclair, J. R. et al. Post-translational modification by cysteine protects  
Cu/Zn-superoxide dismutase from oxidative damage. Biochemistry 52, 
6137–6144 (2013).
 21. Ayaz-Guner, S., Zhang, J., Li, L., Walker, J. W. & Ge, Y. In vivo 
phosphorylation site mapping in mouse cardiac troponin I by high resolution 
top-down electron capture dissociation mass spectrometry: Ser22/23 are the 
only sites basally phosphorylated. Biochemistry 48, 8161–8170 (2009).
 22. Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches 
global histone methylation and alters gene expression in t(4;14) multiple 
myeloma cells. Blood 117, 211–220 (2011).
 23. Wu, D., Struwe, W. B., Harvey, D. J., Ferguson, M. A. J. & Robinson, C. V. 
N-glycan microheterogeneity regulates interactions of plasma proteins.  
Proc. Natl Acad. Sci. USA 115, 8763 (2018).
 24. Doll, S. & Burlingame, A. L. Mass spectrometry-based detection and 
assignment of protein posttranslational modifications. ACS Chem. Biol. 10, 
63–71 (2015).
 25. Chait, B. T. Mass spectrometry: bottom-up or top-down? Science 314, 65 (2006).
 26. Wessel, D. & Flügge, U. I. A method for the quantitative recovery of protein 
in dilute solution in the presence of detergents and lipids. Anal. Biochem. 
138, 141–143 (1984).
 27. Fornelli, L. et al. Top-down proteomics: where we are, where we are going?  
J. Proteomics 75, 3–4 (2017).
 28. Dang, X. et al. The first pilot project of the Consortium for Top-Down 
Proteomics: a status report. Proteomics 14, 1130–1140 (2014).
 29. Cech, N. B. & Enke, C. G. Practical implications of some recent studies in 
electrospray ionization fundamentals. Mass Spectrom. Rev. 20, 362–387 (2001).
 30. Metwally, H., McAllister, R. G. & Konermann, L. Exploring the mechanism of 
salt-induced signal suppression in protein electrospray mass spectrometry 
using experiments and molecular dynamics simulations. Anal. Chem. 87, 
2434–2442 (2015).
 31. Compton, P. D., Zamdborg, L., Thomas, P. M. & Kelleher, N. L. On the 
scalability and requirements of whole protein mass spectrometry. Anal. Chem. 
83, 6868–6874 (2011).
 32. Karas, M., Bahr, U. & Dülcks, T. Nano-electrospray ionization mass 
spectrometry: addressing analytical problems beyond routine. Fresenius J. 
Anal. Chem. 366, 669–676 (2000).
 33. Juraschek, R., Dulcks, T. & Karas, M. Nanoelectrospray—more than just a 
minimized-flow electrospray ionization source. J. Am. Soc. Mass Spectrom. 10, 
300–308 (1999).
 34. Evershed, R. P., Robertson, D. H., Beynon, R. J. & Green, B. N. Application of 
electrospray ionization mass spectrometry with maximum-entropy analysis to 
allelic ‘fingerprinting’ of major urinary proteins. Rapid Commun. Mass 
Spectrom. 7, 882–886 (1993).
 35. Ferrige, A. G. et al. Disentangling electrospray spectra with maximum 
entropy. Rapid Commun. Mass Spectrom. 6, 707–711 (1992).
 36. Maquin, F., Schoot, B. M., Devaux, P. G. & Green, B. N. Molecular weight 
determination of recombinant interleukin 2 and interferon gamma by 
electrospray ionization mass spectroscopy. Rapid Commun. Mass Spectrom. 5, 
299–302 (1991).
 37. Loo, J. A., Udseth, H. R. & Smith, R. D. Peptide and protein analysis by 
electrospray ionization-mass spectrometry and capillary electrophoresis-mass 
spectrometry. Anal. Biochem. 179, 404–412 (1989).
 38. Morris, H. R. et al. High sensitivity collisionally-activated decomposition 
tandem mass spectrometry on a novel quadrupole/orthogonal-acceleration 
time-of-flight mass spectrometer. Rapid Commun. Mass Spectrom. 10, 
889–896 (1996).
NATURe MeTHODS | VOL 16 | JULY 2019 | 587–594 | www.nature.com/naturemethods 593
PersPective NaTure MeTHODs
 39. Kelleher, N. L., Senko, M. W., Little, D. P., O’Connor, P. B. & McLafferty, F. W. 
Complete large-molecule high-resolution mass spectra from 50-femtomole 
microvolume injection. J. Am. Soc. Mass Spectrom. 6, 220–221 (1995).
 40. LeDuc, R. D., Schwammle, V., Shortreed, M. R. & Cesnik, A. J. ProForma: a 
standard proteoform notation. J. Proteome Res. 17, 1321–1325 (2018).
 41. Shaw, K. L., Grimsley, G. R., Yakovlev, G. I., Makarov, A. A. & Pace, C. N. 
The effect of net charge on the solubility, activity, and stability of ribonuclease 
Sa. Protein Sci. 10, 1206–1215 (2001).
 42. Konermann, L. Addressing a common misconception: ammonium acetate as 
neutral pH “buffer” for native electrospray mass spectrometry. J. Am. Soc. 
Mass Spectrom. 28, 1827–1835 (2017).
 43. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 
1260419 (2015).
 44. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets 
are there? Nat. Rev. Drug Discov. 5, 993 (2006).
 45. Laganowsky, A., Reading, E., Hopper, J. T. S. & Robinson, C. V. Mass 
spectrometry of intact membrane protein complexes. Nat. Protoc. 8,  
639–651 (2013).
 46. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal  
sample preparation method for proteome analysis. Nat. Methods 6,  
359–362 (2009).
 47. Erde, J., Loo, R. R. O. & Loo, J. A. Enhanced FASP (eFASP) to increase 
proteome coverage and sample recovery for quantitative proteomic 
experiments. J. Proteome Res. 13, 1885–1895 (2014).
 48. Doucette, A. A., Vieira, D. B., Orton, D. J. & Wall, M. J. Resolubilization of 
precipitated intact membrane proteins with cold formic acid for analysis by 
mass spectrometry. J. Proteome Res. 13, 6001–6012 (2014).
 49. Güray, M. Z., Zheng, S. & Doucette, A. A. Mass spectrometry of intact 
proteins reveals +98 u chemical artifacts following precipitation in acetone.  
J. Proteome Res. 16, 889–897 (2017).
 50. Smith, R. D., Loo, J. A., Edmonds, C. G., Barinaga, C. J. & Udseth, H. R. New 
developments in biochemical mass spectrometry: electrospray ionization. 
Anal. Chem. 62, 882–899 (1990).
 51. Leney, A. C. & Heck, A. J. R. Native mass spectrometry: what is in the name? 
J. Am. Soc. Mass Spectrom. 28, 5–13 (2017).
 52. Hernández, H. & Robinson, C. V. Determining the stoichiometry and 
interactions of macromolecular assemblies from mass spectrometry.  
Nat. Protoc. 2, 715 (2007).
 53. Lössl, P., Snijder, J. & Heck, A. J. R. Boundaries of mass resolution in native 
mass spectrometry. J. Am. Soc. Mass Spectrom. 25, 906–917 (2014).
 54. Gault, J. et al. High-resolution mass spectrometry of small molecules bound 
to membrane proteins. Nat. Methods 13, 333–336 (2016).
 55. Belov, A. M. et al. Analysis of proteins, protein complexes, and organellar 
proteomes using sheathless capillary zone electrophoresis - native mass 
spectrometry. J. Am. Soc. Mass Spectrom. 28, 2614–2634 (2017).
 56. Belov, A. M. et al. Complementary middle-down and intact monoclonal 
antibody proteoform characterization by capillary zone electrophoresis - mass 
spectrometry. Electrophoresis 39, 2069–2082 (2018).
 57. Tran, J. C. & Doucette, A. A. Multiplexed size separation of intact  
proteins in solution phase for mass spectrometry. Anal. Chem. 81,  
6201–6209 (2009).
 58. Whitelegge, J. P., Gundersen, C. B. & Faull, K. F. Electrospray-ionization  
mass spectrometry of intact intrinsic membrane proteins. Protein Sci. 7, 
1423–1430 (1998).
 59. le Coutre, J. et al. Proteomics on full-length membrane proteins using mass 
spectrometry. Biochemistry 39, 4237–4242 (2000).
 60. Whitelegge, J. P. HPLC and mass spectrometry of intrinsic membrane 
proteins. In HPLC of Peptides and Proteins: Methods and Protocols  
(ed. Aguilar, M.-I.) 323–339 (Springer, 2004).
 61. Souda, P., Ryan, C. M., Cramer, W. A. & Whitelegge, J. Profiling  
of integral membrane proteins and their post translational modifications 
using high-resolution mass spectrometry. Methods 55,  
330–336 (2011).
 62. Whitelegge, J. P. Integral membrane proteins and bilayer proteomics.  
Anal. Chem. 85, 2558–2568 (2013).
 63. Howery, A. E. et al. A designed inhibitor of a CLC antiporter blocks function 
through a unique binding mode. Chem. Biol. 19, 1460–1470 (2012).
 64. Whitelegge, J. P. et al. Toward the bilayer proteome, electrospray ionization-
mass spectrometry of large, intact transmembrane proteins. Proc. Natl Acad. 
Sci. USA 96, 10695–10698 (1999).
 65. Cleland, T. P. et al. High-throughput analysis of intact human proteins using 
UVPD and HCD on an Orbitrap mass spectrometer. J. Proteome Res. 16, 
2072–2079 (2017).
 66. Ansong, C. et al. Top-down proteomics reveals a unique protein S-thiolation 
switch in Salmonella Typhimurium in response to infection-like conditions. 
Proc. Natl Acad. Sci. USA 110, 10153–10158 (2013).
 67. Ntai, I. et al. Applying label-free quantitation to top down proteomics.  
Anal. Chem. 86, 4961–4968 (2014).
 68. Skinner, O. S. et al. Top-down characterization of endogenous protein 
complexes with native proteomics. Nat. Chem. Biol. 14, 36 (2017).
Acknowledgements
J.N.A. was supported in part by NIH R01 NS065263 and ALSA 18-IIA-420 in collaboration 
with Biopharmaceutical Analysis Training Lab at Northeastern University. Y.G. was 
supported by NIH R01 GM117058 and S10 OD018475 and acknowledges the UW-
Madison Human Proteomics Program Mass Spectrometry Facility (initially funded by the 
Wisconsin Partnership Funds). A.R.I. was supported by the NIH awards 1R01GM120272 
and R01CA218500 and acknowledges Thermo Fisher Scientific and SCIEX for their 
support. J.P.W.’s lab was supported in part by the NIH grant P30DK063491. J.A.L. 
acknowledges the NIH (R01 GM103479, S10 RR028893, S10 OD018504) and the US 
Department of Energy (DE-FC-02-02ER63421). J.L.L. acknowledges the postdoctoral 
program at Amgen, Inc. C.L. acknowledges support from the NIH Ruth L. Kirschstein 
National Research Service Award (NRSA; T32 GM007185). Work done by N.L.K. 
was carried out in collaboration with the National Resource for Translational and 
Developmental Proteomics under NIH Grant P41GM108569 from the National Institute 
of General Medical Sciences. The NRTDP would like to thank I. Ntai for assistance in data 
collection. L. Schachner is a Howard Hughes Medical Institute Gilliam Fellow. Research 
reported in this publication was supported by a fellowship associated with the Chemistry of 
Life Processes Predoctoral Training Program T32GM105538 at Northwestern University.
Author contributions
D.P.D. and C.M.R. contributed by making all the figures and writing the manuscript with 
J.N.A. Experiments were performed by D.P.D., C.M.R., C.J.D., L.F., L.F.S., Z.L., J.J.W., 
J.L.L., K.C.A, R.S., K.J., A.K., I.D.G.C., J.R.A., B.C., C. L., W.J., A.R.I. and J.P.W. who all 
contributed data that was incorporated into the final results. L.P., J.C., P.O.D., L.M.S., 
Y.O.T., J.A.L, Y.G., N.L.K. and J.N.A make up the Consortium for Top-Down Proteomics 
Board of Directors who designed and guided this project. All authors contributed to the 
editing and formatting of the manuscript.
Competing interests
Authors with company affiliations include J.L.L. (Amgen), K.C.A. (Alnylam), R.S. 
(Biogen), J.J.W. (Bruker), I.D.G.C. (Amgen), P.O.D. (Eastwoods Consulting) and Y.O.T. 
(Spectroswiss).
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/
s41592-019-0457-0.
Reprints and permissions information is available at www.nature.com/reprints.
Correspondence should be addressed to J.N.A.
Peer review information: Allison Doerr was the primary editor on this article and 
managed its editorial process and peer review in collaboration with the rest of the 
editorial team.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in 
published maps and institutional affiliations.
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2019
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as 
long as you give appropriate credit to the original author(s) and the source, provide a link 
to the Creative Commons license, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons 
license, unless indicated otherwise in a credit line to the material. If material is not 
included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain 
permission directly from the copyright holder. To view a copy of this license, visit http://
creativecommons.org/licenses/by/4.0/.
NATURe MeTHODS | VOL 16 | JULY 2019 | 587–594 | www.nature.com/naturemethods594
